Institute of General Practice and Evidence-Based Health Services Research, Medical University of Graz, Graz, Austria.
Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
Cochrane Database Syst Rev. 2021 Feb 8;2(2):CD008274. doi: 10.1002/14651858.CD008274.pub4.
All major guidelines for antihypertensive therapy recommend weight loss. Dietary interventions that aim to reduce body weight might therefore be a useful intervention to reduce blood pressure and adverse cardiovascular events associated with hypertension.
Primary objectives To assess the long-term effects of weight-reducing diets in people with hypertension on all-cause mortality, cardiovascular morbidity, and adverse events (including total serious adverse events, withdrawal due to adverse events, and total non-serious adverse events). Secondary objectives To assess the long-term effects of weight-reducing diets in people with hypertension on change from baseline in systolic blood pressure, change from baseline in diastolic blood pressure, and body weight reduction.
For this updated review, the Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to April 2020: the Cochrane Hypertension Specialised Register, CENTRAL (2020, Issue 3), Ovid MEDLINE, Ovid Embase, and ClinicalTrials.gov. We also contacted authors of relevant papers about further published and unpublished work. The searches had no language restrictions.
We included randomised controlled trials (RCTs) of at least 24 weeks' duration that compared weight-reducing dietary interventions to no dietary intervention in adults with primary hypertension.
Two review authors independently assessed risks of bias and extracted data. Where appropriate and in the absence of significant heterogeneity between studies (P > 0.1), we pooled studies using a fixed-effect meta-analysis. In case of moderate or larger heterogeneity as measured by Higgins I, we used a random-effects model.
This second review update did not reveal any new trials, so the number of included trials remains the same: eight RCTs involving a total of 2100 participants with high blood pressure and a mean age of 45 to 66 years. Mean treatment duration was 6 to 36 months. We judged the risks of bias as unclear or high for all but two trials. No study included mortality as a predefined outcome. One RCT evaluated the effects of dietary weight loss on a combined endpoint consisting of the necessity of reinstating antihypertensive therapy and severe cardiovascular complications. In this RCT, weight-reducing diet lowered the endpoint compared to no diet: hazard ratio 0.70 (95% confidence interval (CI) 0.57 to 0.87). None of the trials evaluated adverse events as designated in our protocol. The certainty of the evidence was low for a blood pressure reduction in participants assigned to weight-loss diets as compared to controls: systolic blood pressure: mean difference (MD) -4.5 mm Hg (95% CI -7.2 to -1.8 mm Hg) (3 studies, 731 participants), and diastolic blood pressure: MD -3.2 mm Hg (95% CI -4.8 to -1.5 mm Hg) (3 studies, 731 participants). We judged the certainty of the evidence to be high for weight reduction in dietary weight loss groups as compared to controls: MD -4.0 kg (95% CI -4.8 to -3.2) (5 trials, 880 participants). Two trials used withdrawal of antihypertensive medication as their primary outcome. Even though we did not consider this a relevant outcome for our review, the results of these RCTs strengthen the finding of a reduction of blood pressure by dietary weight-loss interventions.
AUTHORS' CONCLUSIONS: In this second update, the conclusions remain unchanged, as we found no new trials. In people with primary hypertension, weight-loss diets reduced body weight and blood pressure, but the magnitude of the effects are uncertain due to the small number of participants and studies included in the analyses. Whether weight loss reduces mortality and morbidity is unknown. No useful information on adverse effects was reported in the relevant trials.
所有主要的降压治疗指南都建议减肥。因此,旨在减轻体重的饮食干预可能是降低血压和与高血压相关的不良心血管事件的有用干预措施。
主要目的评估减肥饮食对高血压患者的全因死亡率、心血管发病率和不良事件(包括总严重不良事件、因不良事件退出和总非严重不良事件)的长期影响。次要目的评估减肥饮食对高血压患者的收缩压从基线变化、舒张压从基线变化和体重减轻的长期影响。
对于本次更新的综述,Cochrane 高血压信息专家在 Cochrane 高血压特藏、CENTRAL(2020 年第 3 期)、Ovid MEDLINE、Ovid Embase 和 ClinicalTrials.gov 中搜索了截至 2020 年 4 月的随机对照试验。我们还联系了相关论文的作者,了解进一步发表和未发表的工作。搜索没有语言限制。
我们纳入了至少持续 24 周的随机对照试验(RCT),比较了原发性高血压成人中减肥饮食干预与无饮食干预的效果。
两名综述作者独立评估了偏倚风险并提取了数据。如果适当且研究之间没有显著的异质性(P > 0.1),我们使用固定效应荟萃分析对研究进行了合并。如果用 Higgins I 测量存在中度或更大的异质性,则使用随机效应模型。
本次第二更新未发现任何新试验,因此纳入的试验数量保持不变:八项 RCT 共涉及 2100 名高血压患者,平均年龄为 45 至 66 岁。平均治疗时间为 6 至 36 个月。我们判断除了两项试验之外,所有试验的偏倚风险都不明确或很高。没有研究将死亡率作为预设结局。一项 RCT 评估了饮食减肥对由需要重新开始抗高血压治疗和严重心血管并发症组成的复合终点的影响。在这项 RCT 中,与不节食相比,节食降低了终点:风险比 0.70(95%置信区间(CI)0.57 至 0.87)。没有一项试验将不良事件作为我们方案中指定的结局进行评估。与对照组相比,减肥饮食对参与者血压降低的证据确定性为低:收缩压:平均差值(MD)-4.5mmHg(95%CI-7.2 至-1.8mmHg)(3 项研究,731 名参与者),舒张压:MD-3.2mmHg(95%CI-4.8 至-1.5mmHg)(3 项研究,731 名参与者)。我们判断减肥饮食组体重减轻的证据确定性为高:MD-4.0kg(95%CI-4.8 至-3.2)(5 项研究,880 名参与者)。两项试验将停止使用抗高血压药物作为其主要结局。尽管我们认为这不是我们综述的相关结局,但这些 RCT 的结果加强了饮食减肥干预降低血压的发现。
在本次第二更新中,结论保持不变,因为我们没有发现新的试验。在原发性高血压患者中,减肥饮食可降低体重和血压,但由于纳入分析的参与者和研究数量较少,其效果的幅度仍不确定。减肥是否降低死亡率和发病率尚不清楚。相关试验未报告有关不良影响的有用信息。